Smoking cessation counseling in patients with T2DM and TUD (without obesity) (Comparision between matched semaglutide vs other anti-diabetes medications cohorts)

Size/cohort	Exposure	Comparison	cases (overall risk) (Exposure)	cases (overall risk) (Comparison)	RD (95% CI)			HR (95% CI)
1,302	semaglutide	insulins	28 (2.1%)	26 (2.0%)	0.2% (-0.9%, 1.2%)	├		0.95 (0.56–1.62)
1,305	semaglutide	metformin	29 (2.2%)	48 (3.7%)	-1.5% (-2.8%, -0.2%)			0.58 (0.37–0.82)
1,283	semaglutide	DPP-4i	27 (2.1%)	38 (3.0%)	-0.9% (-2.1%, 0.4%)	-		0.69 (0.42–1.13)
1,293	semaglutide	SGLT2i	29 (2.2%)	31 (2.4%)	-0.2% (-1.3%, 1.0%)			0.90 (0.54–1.49)
1,292	semaglutide	SU	27 (2.1%)	50 (3.9%)	-1.8% (-3.1%, -0.5%)			0.52 (0.32–0.83)
1,033	semaglutide	TZD	21 (2.0%)	27 (2.6%)	-0.6% (-1.9%, 0.7%)			0.73 (0.41–1.29)
1,268	semaglutide	other GLP-1RAs	26 (2.1%)	39 (3.1%)	-1.0% (-2.3%, 0.2%)	—	 	0.64 (0.39–1.05)
					0	.30 0.40 0.60 0.801 Hazard Ra		3.00